scholarly journals Atherogenic index of plasma and left ventricular ejection fraction in newly diagnosed type 2 diabetes mellitus patients

2021 ◽  
Vol 10 (3) ◽  
pp. 73
Author(s):  
Himel Mondal ◽  
Shaikat Mondal ◽  
Ritushri Samantaray ◽  
Debasish Das ◽  
SairaviKiran Biri ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Left Ventricular ◽  
Atherogenic Index ◽  
Left Ventricular Ejection ◽  
Newly Diagnosed ◽  
Ventricular Ejection Fraction ◽  
Atherogenic Index Of Plasma

The clinical and experimental analysis of ventricular rhythm disturbances in the patients with type 2 diabetes mellitus suffering from diastolic cardiac insufficiency

2015 ◽  
Vol 61 (2) ◽  
pp. 21-27
Author(s):  
I P Tatarchenko ◽  
N V Pozdnyakova ◽  
A G Denisova ◽  
O I Morozova
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Diastolic Dysfunction ◽  
Left Ventricular ◽  
Cardiac Insufficiency ◽  
Left Ventricular Ejection ◽  
Ventricular Extrasystole ◽  
Ventricular Ejection Fraction

The present study was focused on the assessment of electrophysiological, structural, and functional characteristics of the heart associated with ventricular rhythm disturbances in the patients with type 2 diabetes mellitus (DM2) suffering from diastolic cardiac insufficiency. The study involved a total of 128 patients with DM2 and coronary heart disease (CHD) exhibiting signs of functional class I-III chronic cardiac insufficiency and left ventricular ejection fraction over 50%. The patients were divided into three groups. Group 1 (n=55) included patients presenting with left ventricular relaxation. Group 2 (n=44) was comprised of the patients with the pseudo-normal type of diastolic dysfunction. Group 3 (n=29) consisted of the patients with restrictive diastolic dysfunction. The patients of the latter group were characterized by the high frequency of complicated forms of ventricular arrhythmia, such as Grade IV-V ventricular extrasystole (48.3%) and Grade III ventricular extrasystole (34.5%). Restrictive type of diastolic dysfunction was associated with the delayed fragmented activity in the end part of the ventricular complex in 72.4% of the patients. The close correlation between the left ventricular diastolic function and parameters of myocardial electrical remodeling was documented.

scholarly journals Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Circulation ◽  
2019 ◽  
Vol 139 (3) ◽  
pp. 351-361 ◽  
Author(s):  
Darren K. McGuire ◽  
John H. Alexander ◽  
Odd Erik Johansen ◽  
Vlado Perkovic ◽  
Julio Rosenstock ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Kidney Disease ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Atherosclerotic Cardiovascular Disease ◽  
Ventricular Ejection Fraction ◽  
History Of

Background: Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes with the dipeptidyl peptidase-4 inhibitor linagliptin versus placebo in CARMELINA (The Cardiovascular and Renal Microvascular Outcome Study With Linagliptin), a cardiovascular outcomes trial that enrolled participants with type 2 diabetes mellitus and atherosclerotic cardiovascular disease and/or kidney disease. Methods: Participants in 27 countries with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease were randomized 1:1 to receive once daily oral linagliptin 5 mg or placebo, on top of standard of care. All hospitalization for HF (hHF), cardiovascular outcomes, and deaths were prospectively captured and centrally adjudicated. In prespecified and post hoc analyses of HF and related events, Cox proportional hazards models adjusting for region and baseline history of HF were used. Recurrent hHF events were analyzed using a negative binomial model. In a subset of participants with left ventricular ejection fraction captured within the year before randomization, HF-related outcomes were assessed in subgroups stratified by left ventricular ejection fraction > or ≤50%. Results: CARMELINA enrolled 6979 participants (mean age, 65.9 years; estimated glomerular filtration rate, mL/min per 1.73m 2 ; hemoglobin A1c, 8.0%; 62.9% men; diabetes mellitus duration, 14.8 years), including 1873 (26.8%) with a history of HF at baseline. Median follow-up was 2.2 years. Linagliptin versus placebo did not affect the incidence of hHF (209/3494 [6.0%] versus 226/3485 [6.5%], respectively; hazard ratio [HR], 0.90; 95% CI, 0.74–1.08), the composite of cardiovascular death/hHF (HR, 0.94; 95% CI, 0.82–1.08), or risk for recurrent hHF events (326 versus 359 events, respectively; rate ratio, 0.94; 95% CI, 0.75–1.20). There was no heterogeneity of linagliptin effects on hHF by history of HF at baseline, baseline estimated glomerular filtration rate or urine albumin-creatinine ratio, or prerandomization left ventricular ejection fraction. Conclusions: In a large, international cardiovascular outcome trial in participants with type 2 diabetes mellitus and concomitant atherosclerotic cardiovascular disease and/or kidney disease, linagliptin did not affect the risk of hHF or other selected HF-related outcomes, including among participants with and without a history of HF, across the spectrum of kidney disease, and independent of previous left ventricular ejection fraction. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01897532.

scholarly journals Clinical and instrumental characteristics and five-year survival of men and women with chronic heart failure and reduced left ventricular ejection fraction depending on the presence of type II diabetes mellitus

2020 ◽  
Vol 27 (5) ◽  
pp. 60-70
Author(s):  
L. G. Voronkov ◽  
N. A. Tkach ◽  
O. L. Filatova ◽  
T. I. Gavrilenko ◽  
G. Ye. Dudnik ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Heart Failure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Study Groups ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Ventricular Ejection Fraction ◽  
Atrial Size

The aim – to compare clinical and instrumental parameters and cumulative survival of women and men with chronic heart failure (CHF) and reduced left ventricular ejection fraction (LV EF), depending on the presence of type II diabetes mellitus.Materials and methods. A retrospective analysis of 490 case histories of patients observed in the heart failure department in the period from 2011 to 2018, with CHF, II–IV NYHA functional class, LVEF ≤ 40 %, 40–80 years of age (median (quartiles)) – 64 (56.00; 69.00) years). The study group included mainly patients with coronary heart disease in combination with hypertension – 403 (82.2 %) patients, with isolated coronary heart disease – 55 (11.2 %) and with isolated hypertension – 32 (6.6 %). Most patients (278 (56.7 %)) had a permanent form of atrial fibrillation. Among the subjects were 373 (76.1 %) men and 117 (23.9 %) women. Comparisons were performed in populations of men and women depending on the presence of type 2 diabetes. Patients were included in the study in the phase of clinical compensation, in the euvolemic state.Results and discussion. The analysis revealed that the prevalence of type 2 diabetes mellitus in the population of men with CHF and reduced LV EF is significantly lower than in the female population. There were no significant differences between the study groups by etiology, the NYHA class, as well as the structure of comorbid conditions. Also there were no significant differences in age, mean daily heart rate, systolic and diastolic blood pressure. Despite expectations, insulin levels in both male and female cohorts did not differ significantly in patients with and without concomitant diabetes. In the cohort of men with CHF and reduced LV EF with concomitant diabetes the body mass index, anteroposterior left atrial size, GFR values were significantly higher, whereas the level of circulating citrulline and urea nitrogen were significantly lower compared to women. Women with CHF with reduced LV EF and concomitant diabetes compared to women without diabetes had lower LV EF and left atrial size, higher circulating citrulline levels, and E/е´ ratios. Analysis of the kidneys functional state showed deterioration of nitrogen excretory function in all study groups in the presence of type 2 diabetes mellitus. The five-year survival of men with CHF and reduced LV EF did not differ depending on the presence of type 2 diabetes mellitus. Instead, when analyzing the effect of type 2 diabetes mellitus on life expectancy in women with CHF and reduced LV EF, we observed a significantly worse prognosis.Conclusions. Woman with CHF and reduced LV EF with concomitant type 2 diabetes mellitus is characterized by a worse clinical course of the disease, which is combined with signs of more pronounced damage to target organs (heart, kidneys). At the same time, in women with diabetes, compared with men, the nitrogen-excreting renal function is significantly lower. Cumulative 5-year survival in the male cohort depending on presence of diabetes did not differ, while women with diabetes were characterized by significantly lower 5-year survival compared to women without diabetes.

Effects of epigallocatechin-3-gallate of Camellia sinensis leaves on blood pressure, lipid profile, atherogenic index of plasma and some inflammatory and antioxidant markers in type 2 diabetes mellitus patients: a clinical trial

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Hadi Bazyar ◽  
Seyed Ahmad Hosseini ◽  
Sirous Saradar ◽  
Delsa Mombaini ◽  
Mohammad Allivand ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Lipid Profile ◽  
Atherogenic Index ◽  
Control Group ◽  
Atherogenic Index Of Plasma ◽  
The Mean

Abstract Background In patients with type 2 diabetes mellitus (T2DM) the inflammatory and metabolic responses to epigallocatechin-3-gallate (EGCG) are unknown. Objectives Evaluate the impacts of EGCG on metabolic factors and some biomarkers of stress oxidative in patients with T2DM. Methods In this randomized, double-blind, placebo-controlled trial, 50 patients with T2DM consumed either 2 tablets (300 mg) EGCG (n=25) or wheat flour as placebo (n=25) for 2 months. The total antioxidant capacity (TAC), interleukin-6 (IL-6), lipid profile, mean arterial pressure (MAP), atherogenic index of plasma (AIP) were evaluated before and after the intervention. Results The finding of present study exhibited a significant increase in the serum levels of TAC after the EGCG supplementation (p=0.001). Also, in compare with control group, the mean changes of TAC were significantly higher in supplement group (p=0.01). In intervention group, a significant decrease was observed in the mean levels of triglyceride, total cholesterol, diastolic blood pressure (DBP), AIP, and MAP (p<0.05). Taking EGCG resulted in the mean changes of total cholesterol, MAP and DBP were significantly lower in compare with control group (p<0.05). Conclusions This study recommended that EGCG supplementation may be improved blood pressure, lipid profile, AIP, and oxidative status in patients with T2DM.

scholarly journals Atherogenic index of plasma is associated with major adverse cardiovascular events in patients with type 2 diabetes mellitus

2021 ◽  
Author(s):  
Liyao Fu ◽  
Ying Zhou ◽  
Jiaxing Sun ◽  
Zhaowei Zhu ◽  
Zhenhua Xing ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Events ◽  
Atherogenic Index ◽  
Confounding Factors ◽  
Atherogenic Index Of Plasma ◽  
All Cause Mortality ◽  
Study Population

Abstract Background Previous studies have reported the prognostic value of the atherogenic index of plasma (AIP) in the course of atherosclerosis and other cardiovascular diseases (CVDs). However, the utility of the AIP for prediction is unknown among patients with type 2 diabetes mellitus (T2DM). Methods This was a secondary analysis of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study which randomized 10,251 patients with long-lasting T2DM. ROC curve analysis was used to determine an optimal threshold for AIP and the study population was divided into high and low AIP groups. Univariate and multivariate Cox proportional hazards regression analyses were used to find the association between AIP and primary (MACEs) and second outcomes (all-cause mortality). Stratified analyses were performed to control the confounding factors. Results AIP was an independent risk factor for the prognosis of T2DM (HR = 1.309; 95% CI, 1.084–1.581; P = 0.005). The threshold for AIP was determined to be 0.34 among the study population. After adjustments for confounding factors, multivariate analysis showed that AIP was associated with the risk of MACEs (Model 1: HR = 1.333, 95%CI: 1.205–1.474, P༜0.001; Model 2: HR = 1.171, 95%CI: 1.030–1.333, P = 0.016; Model 3: HR = 1.194, 95%CI: 1.049–1.360, P = 0.007) and all-cause mortality (Model 1: HR = 1.184, 95%CI: 1.077–1.303, P༜0.001), especially cardiovascular deaths (Model 1: HR = 1.422, 95%CI: 1.201–1.683, P༜0.001; Model 3: HR = 1.264, 95%CI: 1.015–1.573, P = 0.036) and nonfatal myocardial infarction (Model 1: HR = 1.447, 95%CI: 1.255–1.669, P༜0.001; Model 2: HR = 1.252, 95%CI: 1.045–1.499, P = 0.015; Model 3: HR = 1.284, 95%CI: 1.071–1.539, P = 0.007). Subgroup stratified analyses showed that AIP might interact with gender, a classical risk factor of cardiovascular events. Conclusions Our study showed that AIP might be a strong biomarker that could be used to predict the risk of cardiovascular events in patients with T2DM.

“COMPARISON OF ATHEROGENIC INDEX OF PLASMA AND CHOLESTEROL/HDL RATIO AMONG TYPE 2 DIABETES MELLITUS PATIENTS IN A TERTIARY CARE HOSPITAL”

2021 ◽  
pp. 52-54
Author(s):  
Amrita Karmakar ◽  
Dipa Mandal ◽  
Soma Gupta
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Risk Group ◽  
Atherogenic Index ◽  
P Value ◽  
Atherogenic Index Of Plasma ◽  
Lipid Ratios ◽  
Cardio Vascular

Lipid prole though is a well established parameter to predict cardio vascular risk in patients suffering from type 2 diabetes mellitus(T2DM), at present lipid ratios are replacing these age old parameters. Among the lipid ratios Atherogenic index of plasma(AIP) and cholesterol/HDL(Chol/HDL) are found to be of great signicance. This cross-sectional study aimed to compare the predictive value of two lipid ratios, "Atherogenic index of plasma" (AIP) and "Cholesterol/HDL ratio" on basis of insulin resistance (IR) among 55 newly diagnosed cases with Type 2 Diabetes Mellitus (T2DM) and 50 control subjects. HOMA –IR (p value <0.0001), AIP (<0.001) and Cholesterol/HDL ratio (<0.001) were signicantly raised among case group in comparison to controls. Both AIP(r- 0.305, p-0.002) and Chol/HDL ratio(r- 0.23, p value- 0.018) was signicantly correlated with HOMA-IR. ROC curve of AIP and Chol/HDL ratio was plotted for identifying IR. There is no signicant difference between areas under curve (AUC) of AIP (AUC-0.656) and Chol/HDL ratio(AUC-0.630) (p value- 0.49). AIP was found to be correlated better with Insulin resistance than CHOL/HDL ratio. AUC in AIP was found to be slightly higher and overall sensitivity and specicity of AIP was found to be 66% and 69%, of Chol/HDL ratio was 46% and 76% to identify moderate to high-risk group: whereas it is 69%&47% of AIP and 87% and 32% of Chol/HDL ratio to identify low risk group. Both lipid ratios have some signicance in predicting cardio vascular risk in T2DM

scholarly journals Evaluation of lipid profile pattern and atherogenic index of plasma (AIP) having type-2 diabetes mellitus in Bangladesh

2018 ◽  
Vol 6 (3) ◽  
pp. 776
Author(s):  
Mahfuza Anjum ◽  
Md. Salah Uddin ◽  
Naima Ahmed Tamanna ◽  
Md. Abdullah Al-Zobair ◽  
A. T. M. Mijanur Rahman
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Density Lipoprotein ◽  
Atherogenic Index ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Atherogenic Index Of Plasma ◽  
Type 2 Diabetic

Background: Dyslipidemia has been noted to play an integral role in the pathogenesis and progression of micro and macrovascular complications in Diabetes Mellitus (DM) patients. The study was aimed to evaluate the prevalence and pattern of dyslipidemia and atherogenic index of plasma (AIP) in type 2 diabetes mellitus patients as it has not been reported previously in BangladeshMethods: This cross-sectional study was conducted at Armed Forces Institute of pathology, Bangladesh from November 2016 to October 2017. A total number of 300 patients having diabetes in the age group of 30-60 years have been selected using a non-probability method. Fasting plasma glucose (FPG), serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels were estimated by laboratory tests.Results: The prevalence of dyslipidemia in at least one lipid parameter was found in 282 patients (94%), while 18 patients (6%) had no dyslipidemia. High levels of TC, TG and LDL-C were found in 134 (47.3%), 230 (76.7%) and 124 (41.3%) patients, respectively. On the other hand, low levels of HDL-C were found in 180 patients (60%). An increased risk of AIP was found in 298 patients (99.3%), whereas only 2 patients (0.7%) were in low risk. FPG was positively correlated with TC, TG, LDL-C and AIP, while negatively correlated with HDL-C. A significant positive correlation was also observed between FPG and AIP.Conclusions: The Study revealed that dyslipidemia is very common in type 2 diabetic patients and the most common abnormality observed was increased serum triglyceride levels followed by decreased serum HDL-C levels. The AIP is also significantly higher in type 2 diabetic patients.

Sign in / Sign up

Export Citation Format

Share Document